More About Dr. Jerry Avorn
A critic of the pharmaceutical industry, Avorn believes companies are now somewhat more cautious, primarily because the FDA has become more vigilant.
Innovation in the pharmaceutical industry is not coming from inside large companies, but from the purchase of biotech start-ups.
Even when good clinical trial data on a regimen or medicine exist, no coherent system ensures that the message gets out to doctors and patients. As a result, many treatment choices are driven by habit, old information or glitzy promotional campaigns.
A letter to Congressman Henry Waxman expressing concerns regarding FDA enforcement.
There is one area of biomedicine in which the government allows even defends a minimal standard that would be unacceptable anywhere else in research. It is the set of evidentiary requirements maintained by the FDA for the approval of new drugs.
There are a few areas in which the government is indispensable. First is its public health role in making sure that all drugs on the market are safe and effective. The second crucial role for government is to make sure that every citizen has the capacity to pay for needed medical care, and that includes drugs.
Report on the state of the FDA's drug testing policies.
Vigilance disappears when it comes to requiring and analyzing the data that we need to be able to learn about the safety of the drugs once they're in widespread use.